Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present OncBioMune Pharmaceuticals, Inc. (OTC: OBMP).

Full DD Report for OBMP

You must become a subscriber to view this report.


Recent News from (OTC: OBMP)

OncBioMune's Phase 2 Clinical Trial of ProscaVax for Early-Stage Prostate Cancer is Now Included on ClinicalTrials.gov
BATON ROUGE, La., July 09, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is...
Source: GlobeNewswire
Date: July, 09 2018 11:30
Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains
Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten...
Source: SeekingAlpha
Date: July, 03 2018 15:18
OncBioMune on go with mid-stage study of therapeutic prostate cancer vaccine; shares up 15%
Nano cap OncBioMune Pharmaceuticals ( OTCPK:OBMP +14.8% ) is up on below-average volume on the news that it has engaged a CRO to manage a Phase 2 clinical trial assessing lead candidate ProscaVax for the first-line treatment of patients with localized prostate cancer, the first mid-stage...
Source: SeekingAlpha
Date: July, 02 2018 15:06
OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Early Stage Prostate Cancer
BATON ROUGE, La., July 02, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, to...
Source: GlobeNewswire
Date: July, 02 2018 14:37
OncBioMune to Commence Phase 2 Trial of ProscaVax for Early Stage Prostate Cancer Patients
BATON ROUGE, La., June 20, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is...
Source: GlobeNewswire
Date: June, 20 2018 08:00
OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May
NEW YORK , June 6, 2018 /PRNewswire/ --   OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective OTCQX® and OTCQB® markets and Caveat Emptor Designations for th...
Source: PR Newswire
Date: June, 06 2018 16:00
OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial
BATON ROUGE, La., March 28, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, i...
Source: GlobeNewswire
Date: March, 28 2018 09:10
Scientific Review Committee Meets on OncBioMune's Phase 2 Prostate Cancer Clinical Trial
BATON ROUGE, La., March 22, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, i...
Source: GlobeNewswire
Date: March, 22 2018 09:00
OncBioMune Announces Presentation at the 2018 AACR Annual Meeting
BATON ROUGE, La., March 20, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, t...
Source: GlobeNewswire
Date: March, 20 2018 09:03
OncBioMune Appoints Robert Neal Holcomb to Board of Directors
BATON ROUGE, La., March 19, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, t...
Source: GlobeNewswire
Date: March, 19 2018 09:23

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-100.0130.01150.0130.0115350,500
2018-12-070.0130.01270.01360.0127681,042
2018-12-060.01490.0120.01490.012278,691
2018-12-050.01330.01110.01330.011580,415
2018-12-040.01330.01110.01330.011580,415

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-109,000350,5002.5678Cover
2018-12-07164,043681,04224.0871Cover
2018-12-0691,092278,69132.6857Cover
2018-12-04139,657580,41524.0616Cover
2018-12-0314,592198,0427.3681Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on OBMP.


About OncBioMune Pharmaceuticals, Inc. (OTC: OBMP)

Logo for OncBioMune Pharmaceuticals, Inc. (OTC: OBMP)

Marketing and distribution of hospital specialty pharmaceutical prescription products.

 

Contact Information

 

 

Current Management

  • Jonathan F. Head / CEO
    • Has served as OncBioMune Pharmaceuticals President and Chief Scientific Officer from until September . He has also been President and Director of Research at the Mastology Research Institute of the ElliottElliottHead Breast Cancer Research and Treatment Center since . Dr. Head is an Adjunct Associate Professor of Biochemistry at Tulane University School of Medicine, an Adjunct Professor of Physical and Biological Sciences at Delta State University and an Adjunct Associate Professor at Louisiana State University School of Veterinary Medicine. Previously, he has held positions in the Division of Cell Biology of Naylor Dana Institute for Disease Prevention of the American Health Foundation in New York, the Department of Immunology at Cornell University Medical School in New York, and the Department of Pediatrics at Mt. Sinai Medical School in New York. He was also Director/Department Head of Tumor Cell Biology at the Center for Clinical Sciences, International Clinical Laboratories in Nashville, Tennessee.
  • Andrew Kucharchuk / CFO
    • served as OncBioMune Pharmaceuticals Chief Financial Officer from to September . Mr. Kucharchuk is a graduate of Louisiana State University and Tulane University s Freeman School of Business, where he earned an MBA with a Finance Concentration.
  • Jeffrey Phillips / EVP, Bus. Affairs
  • Daniel Hoverman /
  • Charles L. Rice /
    • Rice holds a bachelor s degree in business administration from Howard University, a juris doctorate from Loyola University s School of Law and master s degree in business administration from Tulane University. After graduating from Howard University, he was commissioned as a second lieutenant in the United States Army and served as a military intelligence officer with the st Airborne Division Air Assault at Fort Campbell, Ky. While in the Army, he earned the Airborne Badge, Air Assault badge and was awarded the Army Commendation and the Army Achievement medals. He is a member of the Alabama and Louisiana State Bar Associations, the American Bar Association, the New Orleans Bar Association, and the National Bar Association. Mr. Rice s business, regulatory and legal experience give him the skills and appropriate qualifications to serve as a member of our Board.

Current Share Structure

  • Market Cap: $2,937,124 - 03/09/2018
  • Authorized: 500,000,000 - 02/28/2018
  • Issue and Outstanding: 195,808,241 - 02/28/2018
  • Float: 9,773,505 - 09/26/2016

 


Recent Filings from (OTC: OBMP)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 29 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 20 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 14 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: September, 14 2017

 

 


Daily Technical Chart for (OTC: OBMP)

Daily Technical Chart for (OTC: OBMP)


Stay tuned for daily updates and more on (OTC: OBMP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: OBMP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OBMP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of OBMP and does not buy, sell, or trade any shares of OBMP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/